Literature DB >> 6934850

Studies on the comparative distribution and biliary excretion of doxorubicin and 4'-epi-doxorubicin in mice and rats.

M Broggini, T Colombo, A Martini, M G Donelli.   

Abstract

Serum and tissue distribution of doxorubicin (DX) and its stereoisomer, 4'-epidoxorubicin (4'-epiDX), after iv injection of 15 mg/kg was investigated in C57BL mice bearing 14-day intramuscular Lewis lung carcinoma. Total fluorescence was measured together with unchanged drugs, separated, and quantitated by means of thin-layer chromatography combined with a scanning fluorescence technique. In serum the disappearance of 4'-epiDX paralleled that of DX and both unchanged isomers represented < 50% of the total fluorescence measured as early as 30 minutes after drug injection. In tissues the fluorescence measured was almost completely accounted for by the native compounds, both DX and 4'-epiDX, indicating that these drugs are taken up as such by tissues. 4'-EpiDX levels were markedly lower than those of DX in tumor and spleen, whereas in heart, liver, and kidneys the concentrations of the two isomers were the same. Traces of doxorubicinol and possibly 4'-epidoxorubicinol were detected only in serum, liver, and kidneys. Comparative cumulative biliary excretion of DX and 4'-epiDX investigated in the rat indicated that a total of 40%-45% of the injected dose of both drugs was excreted either as unchanged compound or as reduced metabolite. However, the proportions were different and the presence of twice as much reduced metabolite and smaller amounts of native 4'-epiDX suggests that its metabolic rate is different from that of DX

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6934850

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  17 in total

1.  The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats.

Authors:  K S Hall; L Endresen; L Schjerven; H E Rugstad
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.

Authors:  K Kolarić; V Potrebica; J Cervek
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

5.  Comparative metabolism and elimination of adriamycin and 4'-epiadriamycin in the rat.

Authors:  T W Sweatman; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).

Authors:  E E Holdener; H H Hansen; H Høst; U Bruntsch; F Cavalli; J Renard; H M Pinedo; M Rozencweig
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.

Authors:  P A Speth; P C Linssen; L V Beex; J B Boezeman; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

Authors:  N Hartman; P J Basseches; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

10.  Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

Authors:  O Y Hu; S P Chang; J M Jame; K Y Chen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.